自动抗体向未知位的自身免疫脑炎和改性电治疗的影响:三例病例报告
Alternative therapies in health and medicine
|August 13, 2023
概括
改性电疗法 (MECT) 显示为对免疫疗法耐药的自身免疫脑炎 (AE) 病例的辅助治疗有前途. 在AE患者中,MECT有效地控制了精神症状,包括那些有未知的自身抗体和抗N-甲基-D-酸盐受体脑炎的患者.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 精神病学是一个精神病学.
背景情况:
- 自身免疫性脑炎 (AE) 呈现中枢神经系统症状,通常与自身抗体有关.
- 抗N-甲基-D-酸盐受体 (NMDAR) 抗体很常见,但与未知自身抗体的AE越来越多地被识别.
- 标准免疫疗法可能对具有突出精神症状的AE患者不足.
研究的目的:
- 评估改性电疗法 (MECT) 作为AE的辅助治疗.
- 评估MECT在对一线免疫治疗无反应的患者的可行性.
- 总结MECT在AE管理中的临床经验.
主要方法:
- 对三起AE案件的回顾性分析.
- 两个病例涉及针对未知的表位体的自身抗体;一个涉及抗NMDAR脑炎.
- 所有患者都接受了MECT作为耐药精神症状的辅助疗法.
主要成果:
- 在所有三个AE患者中,MECT导致了出色的临床结果.
- 患者在MECT后显著改善了精神症状.
- 在AE中MECT的潜在机制仍然需要阐明.
结论:
- 对于特定的AE病例而言,MECT可以成为可行的辅助治疗,这些病例对免疫疗法没有反应.
- 在标准免疫抑制疗法后,应该考虑使用MECT.
- 需要进一步的多中心研究来确认MECT在AE中的疗效.
更多相关视频
08:38Overcoming Unresponsiveness in Experimental Autoimmune Encephalomyelitis EAE Resistant Mouse Strains by Adoptive Transfer and Antigenic Challenge
Published on: April 9, 2012
20.4K
06:19Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
Published on: September 9, 2022
3.7K
相关概念视频
Electroconvulsive Therapy
69
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
69
Arteries of the Lower Limbs
214
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
214
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
346
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
346
Antiepileptic Drugs: Glutamate Antagonists
422
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
422
